5 Best Artificial Intelligence Stocks Under $20 According To Analysts

2. Predictive Oncology Inc. (NASDAQ:POAI)

Average Estimated Price Target: $5.00

Number of Hedge Fund Holders: 2

Average Upside Potential: 1,819.39% 

Predictive Oncology Inc. (NASDAQ:POAI) is an American company that employs artificial intelligence to develop effective cancer treatments. The company operates in four segments – Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides AI-based predictive models to improve patient outcomes by enhancing clinical responses to tumor drug treatments. It also utilizes active learning asset technology for patient-centric drug discovery. On March 17, Predictive Oncology (NASDAQ:POAI) announced that it will distribute a dividend of newly designated Series F Preferred Stock, equivalent to one one-thousandth of a share, for each outstanding common share held by shareholders on record as of March 27. 

On March 17, Predictive Oncology Inc. (NASDAQ:POAI) announced that it has teamed up with Cancer Research Horizons to create cancer medications. To identify the most effective drug-tumor type combinations for clinical development, the collaboration will employ Predictive’s PEDAL technology, an artificial intelligence (AI) and machine learning platform that predicts drug responses. Cancer Research Horizons’ preclinical Glutaminase drug inhibitors will be evaluated by the partnership to determine which cancer types and patient populations are most likely to respond to treatment with these compounds.

According to Insider Monkey’s fourth quarter database, Ken Griffin’s Citadel Investment Group is the biggest stakeholder in Predictive Oncology Inc. (NASDAQ:POAI), with 87,964 shares worth nearly $27 million.